Evidence map›Paper›PMID 27592117›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2016

Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.

Lilian Areal Marques, Simone Cristine Semprebon, Andressa Megumi Niwa, Gláucia Fernanda Rocha D'Epiro, Daniele Sartori, Ângelo de Fátima, Lúcia Regina Ribeiro, Mário Sérgio Mantovani

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022
    Review
  4. Review
  5. Monastrol derivatives:Research in pharmaceutical sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lilian Areal MarquesDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil. lilian.areal.marques@gmail.com.
Simone Cristine SemprebonDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil.
Andressa Megumi NiwaDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil.
Gláucia Fernanda Rocha D'EpiroDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil.
Daniele SartoriDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil.
Ângelo de FátimaDepartamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Lúcia Regina RibeiroDepartamento de Patologia, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, São Paulo, Brazil.
Mário Sérgio MantovaniDepartamento de Biologia Geral, Universidade Estadual de Londrina, Rodovia Celso Garcia CID, PR 445, Km 380, Caixa Postal 10011, Londrina, Paraná, CEP: 86057-970, Brazil.
Universidade Estadual de Londrina · BRUniversidade Estadual Paulista (Unesp) · BRUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. We investigated the antiproliferative effect of monastrol on human breast adenocarcinoma cells (MCF-7) and mammary epithelial cells (HB4a, non-tumoral). Monastrol treatment decreased cell viability only in MCF-7 tumor cells. Real-time cell growth kinetic analysis showed a decrease in the proliferation of MCF-7 cells exposed to monastrol, while in the HB4a cells, only a concentration of 100 μM was able to induce this effect. In a cell cycle analysis, exposure of MCF-7 cells to monastrol led to an increased population of cells in both the G1 and G2/M phases. In HB4a cells, the proportion of cells in the G2/M phase was increased. Monastrol led to an increased mitotic index in both cell lines. Monastrol was not able to induce cell death by apoptosis in any of the cell lines studied. Gene expression analysis was performed to measure the mRNA levels of cell cycle genes, DNA damage indicator gene, and apoptotic related genes. Treatment with monastrol induced in MCF-7 cells a 5-fold increase in the mRNA levels of the CDKN1A gene, an inhibitor of CDKs related with cell cycle arrest in response a stress stimulus, and a 2-fold decrease in CDKN1C mRNA levels in HB4a cells. These results provide evidence that monastrol has a greater antiproliferative effect on MCF-7 tumor cells compared with non-tumor HB4a cells; however, no selective is observed.

Indexed as

AdenocarcinomaAntineoplastic AgentsBreast NeoplasmsCell ProliferationCell SurvivalCyclin-Dependent Kinase Inhibitor p57Dose-Response Relationship, DrugFemaleG1 Phase Cell Cycle CheckpointsG2 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansKineticsMammary Glands, HumanMCF-7 CellsMitotic IndexAntineoplastic AgentsCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57monastrolPyrimidinesRNA, MessengerThionesCDKN1AHB4aKinesin 5MCF-7Monastrol

Identifiers

PMID27592117
OpenAlexW2516121219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.